.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,115,618

« Back to Dashboard

Details for Patent: 7,115,618

Title:.alpha.- and .beta.-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
Abstract: .alpha.- and .beta.-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
Inventor(s): Vazquez; Michael J. (Gurnee, IL), Mueller; Richard A. (Glencoe, IL), Talley; John J. (St. Louis, MO), Getman; Daniel P. (Chesterfield, MO), DeCrescenzo; Gary A. (St. Peters, MO), Freskos; John N. (Clayton, MO), Heintz; Robert M. (Ballwin, MO), Bertenshaw; Deborah E. (Brentwood, MO)
Assignee: G.D. Searle & Co. (Chicago, IL)
Filing Date:Mar 30, 2004
Application Number:10/812,343
Claims:1. A retroviral protease inhibiting compound represented by the formula ##STR00497## or a pharmaceutically acceptable salt thereof, wherein: A represents a radical selected from the group consisting of cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aroyl; and cycloalkyl, aryl, heteroaryl or aroyl that is substituted at one or more carbon atoms with a radical selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, amino, alkylamino, dialkylamino, nitro, cyano, haloalkyl, carboxy, alkoxycarbonyl, cycloalkyl, heterocycloallcyl, alkylamido, dialkylamido, alkylsulfonyl, and alkylsulfonylalkyl; and R.sup.3 and R.sup.4 independently represent radicals selected from the group consisting of alkyl; haloalkyl; alkenyl; alkynyl; hydroxyalkyl; alkoxyalkyl; cycloalkyl; cycloalkylalkyl; heterocycloalkyl; heteroaryl; heterocycloalkylalkyl; aryl; aralkyl; heteroaralkyl; aminoalkyl; aminoalkyl substituted at one or more carbon atoms with a radical selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl; and aminoalkyl substituted at two carbon atoms with radicals that, together with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical.

2. The retroviral protease inhibiting compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein: A represents a radical selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.

3. The retroviral protease inhibiting compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein: A represents aryl that is substituted at one or more carbon atoms with a radical selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, amino, alkylamino, dialkylamino, nitro, cyano, haloalkyl, carboxy, alkoxycarbonyl, cycloalkyl, heterocycloalkyl, alkylamido, and dialkylamido.

4. The retroviral protease inhibiting compound of claim 3 or a pharmaceutically acceptable salt thereof, wherein: A represents aryl that is substituted at one or more carbon atoms with a radical selected from the group consisting of alkyl, alkoxy, amino, dimethylamino, nitro, --SO.sub.2CH.sub.3, and --CH.sub.3SO.sub.2CH.sub.3.

5. The retroviral protease inhibiting compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the stereochemistry of the carbon atom attached to the benzyl radical is designated as (S) and the stereochemistry of the adjacent carbon atom attached to the hydroxyl radical is designated as (R).

6. The retroviral protease inhibiting compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of ##STR00498## ##STR00499## ##STR00500## ##STR00501## ##STR00502## ##STR00503##

7. A pharmaceutical composition comprising said retroviral protease inhibiting compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

8. A method of inhibiting a retroviral protease, said method comprising administering a protease inhibition effective amount of said pharmaceutical composition of claim 7.

9. The method of claim 8, wherein said retroviral protease is HIV protease.

10. A method of treating a retroviral infection, said method comprising administering a retroviral treatment effective amount of said pharmaceutical composition of claim 7.

11. The method of claim 10, wherein said retroviral infection is an HIV infection.

12. A method for treating AIDS, said method comprising administering an AIDS treatment effective amount of said pharmaceutical composition of claim 7.

13. A compound represented by the formula: ##STR00504## or a pharmaceutically acceptable salt thereof, wherein P.sup.1 is a hydrogen radical; P.sup.2 represents a radical selected from the group consisting of alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl,heterocyclyloxycarbonyl,heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxycarbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, and aminoalkanoyl; or a mono- or disubstituted aminocarbonyl radical or a mono- or disubstituted aminoalkanoyl radical, having substituents selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl and heterocycloalkyalkyl radicals; or, where said aminoalkanoyl radical is disubstituted, having substituents that, along with the nitrogen atom to which they are attached, form a heterocycloalkyl or heteroaryl radical; R.sup.3 is a radical selected from the group consisting of hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, and aminoalkyl, or a mono- or disubstituted aminoalkyl radical, having substituents selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl and heterocycloalkylalkyl radicals; or where said aminoalkyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical; and R.sup.4 is a radical as defined by R.sup.3 except for hydrogen.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc